OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Cell International is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Identification and validation of ARF6 for a potential prognostic biomarker of acute myeloid leukemia	307
A multi-analyte liquid biopsy approach for nonseminomatous testicular germ cell tumors: combining cfDNA and N-glycan analysis in blood and seminal plasma	266
Mortalin promotes the evolution of androgen-independent prostate cancer through Wnt/β-catenin signaling pathway	240
Human amniotic epithelial cells exert anti-cancer effects through secretion of immunomodulatory small extracellular vesicles (sEV)	189
Syntaxin6 contributes to hepatocellular carcinoma tumorigenesis via enhancing STAT3 phosphorylation	146
PMA exerts anti-leukemia effect in Ph+ ALL through activating PKC δ and its down-stream molecules	139
Evaluation of functional magnetic resonance APT and DKI imaging for breast cancer	134
Revealing a novel Decorin-expressing tumor stromal subset in hepatocellular carcinoma via integrative analysis single-cell RNA sequencing	125
Unraveling the role of the solute carrier family in hepatocellular carcinoma: mechanisms and therapeutic prospects	115
Exploring the role of the disulfidptosis-related gene SLC7A11 in adrenocortical carcinoma: implications for prognosis, immune infiltration, and therapeutic strategies	108
Platinum-based drugs induce phenotypic alterations in nucleoli and Cajal bodies in prostate cancer cells	103
The addition of arginine deiminase potentiates Mithramycin A-induced cell death in patient-derived glioblastoma cells via ATF4 and cytochrome C	101
Deciphering 17-β-hydroxysteroid dehydrogenase 4: from molecular insights to cancer therapeutics	97
ASPM promotes the progression of esophageal squamous cell carcinoma by upregulating the expression of HMMR	92
Curcumin attenuates smoking and drinking activated NF-κB/IL-6 inflammatory signaling axis in cervical cancer	91
Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75	91
Imaging the metabolic reprograming of fatty acid synthesis pathway enables new diagnostic and therapeutic opportunity for breast cancer	86
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors	85
Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma	84
Retraction Note: Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT	84
Transcription factor MYB regulates glycolysis to promote the transfer and malignant progression of gastric cancer through the SSBP2/ISL1 axis	84
MicroRNAome profiling of breast cancer unveils hsa-miR-5683 as a tumor suppressor microRNA predicting favorable clinical outcome	83
Potential role of P4HB in the tumor microenvironment and its clinical prognostic value: a comprehensive pan-cancer analysis and experimental validation with a focus on KIRC	82
Amino acid-based risk stratification model improves prognostic precision in diffuse large B-cell lymphoma	78
Venetoclax synergizes with Wnt/β-catenin inhibitor C-82 in acute myeloid leukemia by increasing the degradation of Mcl-1 protein	76

Targeting the CCL5/CCR5-PI3K-AKT axis suppresses hepatic stellate cell-induced breast cancer metastasis	72
Low NDFIP1-driven metabolic alterations in CD8 + T cells: implications for immune evasion and therapy resistance in HNSC	71
CDK4 inhibition by luteolin enhances lenvatinib sensitivity in HCC via Wnt/β-catenin modulation	71
Shared molecular mechanisms of common differentially expressed genes (C-DEGs) linking gallbladder stones to carcinogenesis: integrated bioinformatics and experimental validation	69
Iron metabolism: backfire of cancer cell stemness and therapeutic modalities	69
Assessment of the anticancer and antimetastatic effects of monocarbonyl analogs of curcumin, C66 and B2BrBC, in breast cancer cells	69
Smad2/3/4 complex could undergo liquid liquid phase separation and induce apoptosis through TAT in hepatocellular carcinoma	66
HOTAIR in cancer: diagnostic, prognostic, and therapeutic perspectives	62
SETDB1 promotes gastric cancer progression via UPR and mTOR pathway	61
Melanoma biology and treatment: a review of novel regulated cell death-based approaches	61
SULF1 regulates malignant progression of colorectal cancer by modulating ARSH via FAK/PI3K/AKT/mTOR signaling	61
TAGLN: a stiffness-driven prognostic biomarker for metastatic colorectal cancer	61
Cuproptosis: a promising new target for breast cancer therapy	58
Molecular mechanisms of microRNA-216a during tumor progression	58
Disclosing a metabolic signature of cisplatin resistance in MDA-MB-231 triple-negative breast cancer cells by NMR metabolomics	58
New models for MPNST: establishment and comprehensive characterization of two tumor cell lines	57
Muscone abrogates breast cancer progression through tumor angiogenic suppression via VEGF/PI3K/Akt/MAPK signaling pathways	57
OTUD3 inhibits breast cancer cell metastasis by regulating TGF-β pathway through deubiquitinating SMAD7	57
Metformin regulates the proliferation and motility of melanoma cells by modulating the LINC00094/miR-1270 axis	57
SLC25A17 inhibits autophagy to promote triple-negative breast cancer tumorigenesis by ROS-mediated JAK2/STAT3 signaling pathway	56
Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression	55
Alantolactone enhances the sensitivity of melanoma to MAPK pathway inhibitors by targeting inhibition of STAT3 activation and down-regulating stem cell markers	54
Construction of a CCL20-centered circadian-signature based prognostic model in cervical cancer	53
Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma	53
TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancer	53
Molecular and phenotypic characterization of 5-FU resistant colorectal cancer cells: toward enrichment of cancer stem cells	52
A multi-omics prognostic model integrating disulfidptosis-related molecular features in colorectal cancer	52